Escherichia coli heat-stable enterotoxin (ST) appears to cause intestinal fluid secretion by activating intestinal particulate guanylate cyclase. Recent studies suggest that chlorpromazine and quinacrine reduce the intestinal secretory response to ST and activation of guanylate cyclase by ST. We have examined the effects of lanthanum chloride, another agent that has been shown to inhibit calcium-dependent cellular processes, on the intestinal secretory response to ST and on the inhibition of ST by chlorpromazine and quinacrine. Lanthanum (2.5 to 10 p.mol per mouse) reduced ST-mediated intestinal fluid secretion in the suckling mouse assay by 40 to 56%, respectively, but did not reduce basal fluid accumulation or ST activation of particulate guanylate cyclase. Intestinal fluid secretion in suckling mice induced by 8-bromocyclic GMP was also reduced by lanthanum. When subeffective doses of lanthanum and chlorpromazine were combined, they blocked both ST-and 8-bromocyclic GMP-mediated gut secretion in suckling mice. Likewise, the combination of subeffective doses of lanthanum and quinacrine reduced ST-mediated gut secretion in suckling mice. However, 8-bromocyclic GMP-induced secretion was not synergistically inhibited by lanthanum and quinacrine. These results suggest that lanthanum blocks ST-induced secretion after ST activation of guanylate cyclase. Additionally, lanthanum potentiates the inhibitory effects of quinacrine and chlorpromazine on ST and suggests that combination antisecretory therapy deserves further exploration.
Escherichia coli heat-stable enterotoxin (ST) appears to cause intestinal fluid secretion by activating intestinal particulate guanylate cyclase. Recent studies suggest that chlorpromazine and quinacrine reduce the intestinal secretory response to ST and activation of guanylate cyclase by ST. We have examined the effects of lanthanum chloride, another agent that has been shown to inhibit calcium-dependent cellular processes, on the intestinal secretory response to ST and on the inhibition of ST by chlorpromazine and quinacrine. Lanthanum (2.5 to 10 p.mol per mouse) reduced ST-mediated intestinal fluid secretion in the suckling mouse assay by 40 to 56%, respectively, but did not reduce basal fluid accumulation or ST activation of particulate guanylate cyclase. Intestinal fluid secretion in suckling mice induced by 8-bromocyclic GMP was also reduced by lanthanum. When subeffective doses of lanthanum and chlorpromazine were combined, they blocked both ST-and 8-bromocyclic GMP-mediated gut secretion in suckling mice. Likewise, the combination of subeffective doses of lanthanum and quinacrine reduced ST-mediated gut secretion in suckling mice. However, 8-bromocyclic GMP-induced secretion was not synergistically inhibited by lanthanum and quinacrine. These results suggest that lanthanum blocks ST-induced secretion after ST activation of guanylate cyclase. Additionally, lanthanum potentiates the inhibitory effects of quinacrine and chlorpromazine on ST and suggests that combination antisecretory therapy deserves further exploration.
Two types of enterotoxins have been associated with enterotoxigenic Escherichia coli diarrhea in humans, a heat-labile toxin (LT) and a heat-stable toxin (ST). The mechanism of action of each toxin is different. LT, like cholera toxin, activates adenylate cyclase in intestinal cells as it induces intestinal fluid secretion (3, 5, 10, 11) . In contrast, ST appears to induce fluid secretion through increased cyclic GMP levels (14) as a result of organ-specific activation of the particulate fraction of guanylate cyclase in intestinal mucosa (J. M. Hughes, F. Murad, and R. L. Guerrant, Clin. Res. 26: 524A, 1978; 6, 12) .
Recent studies of pharmacological interruption of the secretory effects of cholera toxin, LT, and ST have shown that chlorpromazine inhibits the effects induced by these toxins (17, 18, 20) . We and others have shown that chlorpromazine inhibits ST activation of guanylate cyclase and intestinal fluid secretion induced by ST or 8-bromocyclic GMP in suckling mice (1, 9) . Additionally, we have found that quinacrine inhibits the effects induced by ST (R. N. Greenberg, R. 1980) . Although the precise mechanism involved in the inhibition of ST by each of these agents has not been identified, it is known that each agent can inhibit calcium-dependent cellular events. Chlorpromazine binds to calmodulin (an intracellular protein involved in the modulation of some cellular actions of calcium) and inhibits the action of calmodulin (24); quinacrine inhibits phospholipase A2, a calcium-dependent enzyme that liberates arachidonate from phospholipids of the cell membrane (7, 22) . Using Ussing chambers, Field et al. (6) have demonstrated that the removal of calcium from the tissue buffer fails to alter ST responses; however, a role for intracellular calcium pools in the mechanism of ST has not been evaluated. We examined the effects of lanthanum on ST effects because lanthanum, which is similar in molecular size to calcium but which has a higher valency, may displace certain intracellular calcium pools and has been shown to act as a calcium antagonist (23) . In this paper, we report the effect of lanthanum on (i) ST-induced intestinal secretion, (ii) ST Guanylate cyclase assay. Guanylate cyclase activity was determined as described (9) . Reaction mixtures (100 ,ul) contained particulate fractions (14 jig of protein), 50 mM Tris-hydrochloride buffer (pH 7.6), 10 mM theophylline, 3.5 mM creatine phosphate, 7.3 ,ug of creatine phosphokinase, 1 mM GTP, and 4 mM MgCl2. Reaction mixtures were kept at 4°C until the assays were initiated. Assays were initiated with the addition of GTP and MgCI2 and incubated at 37°C for 10 min in the presence of purified ST and lanthanum chloride or control solutions. Incubations were terminated by the addition of 0.9 ml of cold 50 mM sodium acetate buffer (pH 4.0) and subsequent heating for 3 min at 95°C. Cyclic GMP formed was determined by radioimmunoassay (21) with acetylation of samples (15) as described previously (13) . Protein was determined by the method of Lowry et al. (19) , using bovine serum albumin as standard.
Suckling mouse assay. To perform the assay, suckling mice 2 to 3 days old were injected intragastrically (i.g.) with a total of 0.1 ml of various test solutions. All solutions, including dilutions of ST, 8-bromocyclic GMP, and test drugs (expressed as final concentrations in 0.1 ml), were prepared in 50 mM Tris (pH 7.6). The ratio of intestinal weight to remaining body weight was then determined after 3 h as previously described (4, 8) . In some instances, 0.1 ml of lanthanum in 50 mM Tris (pH 7.6) was given subcutaneously (s.c.) at the time of an i.g. injection of ST or 8-bromocyclic GMP. The osmolality of the i.g. solution of ST, 50 mM Tris (pH 7.6), and 50 mM LaCl3 was 251 milliosmolars.
ST preparations. The purified ST used in this assay was prepared from E. coli strain 431 (2) and kindly supplied to us by Donald C. Robertson from the University of Kansas, Lawrence, Kans. The semipurified ST is from a human strain of E. coli (Cl-4): it has a dose response curve comparable to that of the purified ST and activates particulate guanylate cyclase. One unit of either preparation is defined as that amount of ST which produces an intestinal weight/remaining body weight ratio of 0.090 (2) .
The semipurified ST was prepared from a 12-h fermentation of E. coli C1-4 (2). The culture supernatant was collected and passed through a PM-10 Diaflo membrane (Amicon Corp., Lexington, Mass.). The ultrafiltrate was then poured onto an Amberlite XAD-2 column and eluted in 99% methanol-1% acetic acid. After flash evaporation, the material was dialyzed against glass-distilled water for 18 h, using Spectrapor 6 dialysis tubing (1,000 molecular weight cutoff). The dialyzed material was centrifuged at 2,000 x g for 30 min, and the supernatant was then lyophilized. This material was resuspended in 50 mM Tris (pH 7.6) for the suckling mice experiments described in this report. Reagents. Chlorpromazine was provided by Smith Kline & French Laboratories, Philadelphia, Pa. Reagent-grade lanthanum chloride, quinacrine hydrochloride, and 8-bromocyclic GMP were obtained from Sigma Chemical Co., St. Louis, Mo. Other reagents were obtained as described previously (13, 14) .
Statistics. The standard error of the mean was calculated by pooling data from all experiments. The twotailed t-test was used to test the significance of differences between the mean values.
RESULTS
Lanthanum and ST-induced fluid secretion. Lanthanum at 5 ,umol per mouse (0.1 ml of 50 mM LaCl3), given i.g. simultaneously with ST, reduced ST-mediated fluid secretion induced by both 2.5 and 4 U per mouse (P < 0.005) (Fig. 1 ).
This dose of lanthanum did not suppress basal secretion. Instead there is a slight but significant elevation in the basal ratio in the presence of this amount of lanthanum chloride (P < 0.05). Additionally, lanthanum (5 ,umol per mouse), when given s.c. just before an ST dose of 2.5 U per mouse, significantly reduced the intestinal weight/remaining body weight ratio to 0.0843 ± 0.006 (n = 58; P < 0.001). Lanthanum (5 ,umol Lanthanum and ST activation of guanylate cyclase. Lanthanum did not reduce ST (10 U/ml) activation of guanylate cyclase (Fig. 2) . The first set of three bars in Fig. 2 shows the effect of lanthanum on the basal activity of guanylate cyclase. With increasing amounts of lanthanum alone, slight enzyme activation was noted. The activation by 0.1 mM lanthanum chloride is significant (P < 0.05). The second set of three bars shows the effect of lanthanum on ST (10 U! ml)-induced activation of guanylate cyclase; an 11 and 31% increase in guanylate cyclase activi- effect (0.1274 ± 0.004; n = 10). Chlorpromazine (0.1 ,umol per mouse, s.c.) did not significantly reduce the ratio (0.1209 ± 0.006; n = 9). However, these doses of lanthanum chloride and chlorpromazine, which alone did not inhibit ST effects, together significantly reduced the secretory response to 8-bromocyclic GMP (intestinal weight/body weight ratio, 0.1008 + 0.005; n = 21; P < 0.02). In contrast, quinacrine (0.1 ,umol per mouse, s.c.), even with lanthanum chloride at 0.5 p,mol per mouse i.g., did not affect the response to 8-bromocyclic GMP (respective ratios, 0.1217 ± 0.005, n = 10; and 0.1246 ± 0.005, n = 13). DISCUSSION Lanthanum is known to be a relatively specific antagonist of calcium in a variety of biological systems (23) . Because of its similar molecular size but higher valency, it has been suggested that lanthanum binds in place of calcium at welldefined sites on intracellular membranes. Al-.14r though other mechanisms for the inhibitory effects of lanthanum are possible (such as an effect on cell membrane channels for chloride), lanthanum may act as an intracellular calcium antagonist. Because we speculate that the ST inhibitors chlorpromazine and quinacrine may also be acting through inhibition of calmodulin or calcium-dependent membrane phosphates, we examined the effects of lanthanum on STmediated events. The data show (i) that lanthanum chloride inhibits ST-mediated fluid secretion, (ii) that this apparently occurs after ST activation of guanylate cyclase, (iii) that lanthanum chloride enhances the inhibition by chlorpromazine of ST-and 8-bromocyclic GMP-induced intestinal secretion, and (iv) that lanthanum chloride enhances the inhibition by quinacrine of ST-induced but not cyclic GMPinduced intestinal fluid secretion. The specific mechanisms involved with the inhibition of ST by any of these agents has yet to be identified. However, these data suggest that lanthanumsensitive calcium pools may be involved in STand cyclic GMP-mediated intestinal secretion and strengthen the concept that ST-induced secretion occurs through the cyclic GMP pathway. Although concentrations of lanthanum and quinacrine that are subeffective alone act together to inhibit ST-induced secretion, they appear to be acting at different steps. Lanthanum and quinacrine at these concentrations do not act together to reduce 8-bromocyclic GMP-induced secretion. This provides further evidence that quinacrine acts only before guanylate cyclase activation by ST, as we have reported elsewhere (20th ICAAC, abstr. no. 700), and that lanthanum is acting to reduce secretion after cyclic GMP is formed.
Lanthanum inhibition of cholera toxin and E. coli LT-induced secretion has been demonstrated by Leitch and Amer (16) . Their results showed that concentrations of lanthanum greater than 10 mM were required to inhibit the effect of either enterotoxin in a rabbit ileal loop assay and that lanthanum did not inhibit the accumulation of cyclic AMP induced by either enterotoxin. They concluded that lanthanum inhibition of cholera toxin-or LT-mediated gut secretion must have occurred at a site after the generation of the cyclic nucleotide. Their results parallel our findings with ST-and cyclic GMP-induced secretion, and together they suggest that both adenylate and guanylate cyclase-activating enterotoxins (cholera toxin or LT and ST, respectively) cause net secretion in a calcium-dependent manner, perhaps sharing some final common pathways. Further studies with lanthanum as a probe may lead to a better understanding of both the mechanism of action of these enterotoxins and of intestinal fluid secretion. Our findings also indicate the possible role of synergistic pharmacological agents in the therapy of enterotoxin-induced diarrheas as an adjunct to oral glucose-electrolyte therapy.
